The first patient has been dosed with DK210 in a first-in-human, phase 1 clinical trial (NCT05704985) for patients with EGFR-expressing advanced solid tumors.1
“The Diakine™ platform combines the potent anti-cancer function of interleukin-2 [IL-2] with the inflammation-controlling function of interleukin-10 and targets these cytokines to the tumor,” Alexander Spira, MD, PhD, FACP, co-director of the Virginia Cancer Specialists Research Institute, told Targeted OncologyTM.
While IL-2 is known to be toxic, when it is coupled with IL-10, the toxicity is reduced, and its potency is increased. This leads to it being a more tolerable and effective treatment for patients. The agent is the first of several experimental therapeutics developed as part of Deka’s platform of molecules to treat both cancer and inflammatory diseases.